Update, November 13, 2026
Edwards Lifesciences (EW) has risen 5.4% over the past five days to $107.66, outpacing the S&P 500’s 2.0% gain and the XLV health‑care ETF’s 1.9% rise, driven by a fresh 52‑week high and upbeat earnings guidance.
The picture holds: the daily price remains well above the 100‑round support and the 125‑round breakout threshold has not been breached, while the stop at $99.14 and the 90.43 SMA‑50 level stay intact. The stock’s strength metrics (vs SPY +21.2% over 50 days, vs XLV +10.7% over 50 days) continue to align with the bullish assessment.
Recent catalyst coverage includes the earnings beat and raised outlook reported on Investing.com, a Buy rating reaffirmed by TD Cowen, and target upgrades from Wells Fargo and Truist Securities cited by Investing.com. What would change the picture? A weekly close below the 89.26 swing‑zone would prompt a reassessment.
Update, November 6, 2026
Edwards Lifesciences (EW) rose 11.0% over the past five sessions to close at $102.14 on November 6, 2026, a new 52-week high, while the S&P 500 fell 2.7% and XLV slipped 0.04% in the same period. The move was driven by the company's Q3 earnings beat on November 4–5, with sales of $1.72 billion (up 11.2% year-over-year) and adjusted EPS of $0.80, above guidance. Mizuho raised its price target to $120 (Investing.com), Wells Fargo to $113, and Truist upgraded to Buy with a $113 target (Benzinga).
The picture holds. The stock remains above its 40-week average, and the daily trend aligns with the weekly uptrend. The breakout level from the assessment—a daily close above 125.0 on volume above its 20-day average—has not been reached; the stock closed at 102.14, with volume 8% above its 20-day average. Support at 100.0 (round) is intact, and the first crack below that level would be at 93.43 (swing zone). The stop at 99.2 (100.0 minus a quarter of ATR) is still valid. What would change the picture is a weekly close below 89.26 (swing zone). The reward-to-risk to the 150.0 target remains 1.0, below the 3-to-1 threshold, but the stock's relative strength—leading the S&P 500 by 19.6% and XLV by 7.8% over 50 days—supports the bullish stance.
Edwards Lifesciences shares rose 2.1% to $95.23 on November 3, 2026, a new 52-week high, after the company's call on its tricuspid and TAVR trial results. EW has gained 4.9% in five days while the S&P 500 fell 2.1%. The balance of evidence leans positive with high conviction over the next 2 to 6 weeks, though the math from a breakout above $100 does not yet reach 3 to 1.
Why it matters
The event was a conference call in which CEO Bernard Zovighian walked through the CLASP II TR results for the tricuspid valve program and the PROGRESS results in TAVR, per the Seeking Alpha transcript. These are the trials the market had been waiting on. The price response is the clearest verdict available: the stock rose 2.1% during the session and closed at its highest level in a year, so the data did not disappoint.
Nervousness going in was visible. On October 22, Stifel warned of stock risk ahead of the results. Days earlier, the FDA had flagged a heart-valve delivery system issue after a death and injury, and Benzinga described it as a high-risk recall. The shares are up 11.8% over the past month anyway, so by the time the trial data arrived, much of the worry had already been absorbed. The recall has not stopped the advance, but it has not gone away either.
On who drove the move: over five days EW is up 4.9%, XLV is up 2.8%, and the S&P 500 is down 2.1%. The market was a headwind, and the healthcare sector supplied most of the lift. The stock itself added about 2.0 points on top of the sector, which fits a company-specific catalyst but not a dramatic one. Volume today is running 12.5% below its 20-day average, so the push to a new high came on light participation.
The argument about EW is mostly about price versus promise. The bulls have 27 analysts with a consensus of buy and a mean price target of $101.87, with the highest at $117. A Morningstar screen listed a similar consensus target of $102.42 and a forward P/E of 26.6, a neutral presentation that treats the multiple as the price of quality. The cautious side points to the recall, the Stifel warning, and that multiple. At $95.23 the stock sits 6.5% below the mean target and well above the lowest target of $84, so the analyst spread is wide and the shares are in the upper-middle of it.
What the evidence says
The long-term thesis is intact. Price is above its 40-week average, the 50-day average at $88.31 is above the 200-day at $85.53, and the stock is 25.5% above its 52-week low of $75.87. It is up 13.4% over six months and 11.7% year to date, ahead of the S&P 500's 10.5% but behind XLV's 19.0%. The phase is a stock pressing into new highs after a pullback and a consolidation, with the uptrend confirmed on the weekly chart.
For the next 2 to 6 weeks, the balance of evidence leans positive, and conviction is high at 3 of 4 points. The daily trend runs with the weekly uptrend. Over 50 days EW leads the S&P 500 by 9.7% and leads XLV by 1.0%. It is outperforming both the market and its own sector, which is what a trend with institutional support tends to look like.
The strongest case against this is that the stock is stretched going into earnings tomorrow. The 14-day RSI is 73.5, a level that usually means the near-term move has run hard. The new high came on volume below average, and the lead over XLV is only 1.0% over 50 days, thin next to the 9.7% lead on the market. A stock this extended can give back a few points on any earnings stumble, and the recall remains unresolved. None of that breaks the trend or the relative strength, which is why it does not tip the balance. It is why conviction is 3 of 4 rather than 4 of 4.
Levels that matter
The structure holds above $93.43, a swing zone. A move below it would be the first crack. The trend ends below $89.26, another swing zone, and just under it sit the $90 round number and the 50-day average at $88.31. That cluster of support is why a weekly close below $89.26 carries more weight than a dip toward it.
The breakout level is a daily close above $100, a round number, on volume above its 20-day average. From there the first target is $110, also round. The stop sits at $92.77, which is $93.43 minus a quarter of the 14-day ATR of $2.64, since a breakout that falls back under the swing zone would be wrong. That gives 1.4 to 1 reward to risk. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well above the Street-high $117, or an entry much closer to the stop, to change that.
What would change the picture
The rule is a weekly close below $89.26. That would put price under the swing zone that defines the end of the uptrend and, with it, the 50-day average region. The non-price fact most likely to do it is a worsening of the FDA delivery-system issue, such as an expanded recall or further patient harm, or earnings guidance that shows the trial enthusiasm is not translating into valve sales.
What to watch
- Earnings, November 4, 2026: the number that matters is full-year guidance for transcatheter valve sales growth, because it tests whether the trial results change the growth outlook.
- Sector: XLV has done most of the work this week, so a reversal in healthcare, or news on the FDA recall and device-safety actions, can move EW before its own news does.
- Valuation: at $95.23 the shares trade 6.5% under the $101.87 mean target and a forward P/E of 26.6 leaves little room for a disappointing guide.